Yellow fever kills between 30% and 60% of people who develop severe disease, making it one of the deadliest mosquito-borne infections in the world. But most people who contract the virus never reach that severe stage. Roughly 90% of infections are mild or cause no symptoms at all, which means the true population-level death rate is far lower than the headline numbers suggest. The danger lies in the unpredictable leap from a manageable fever to catastrophic organ failure, which happens fast and has no specific treatment.
Most Infections Are Mild or Silent
Yellow fever’s lethality is best understood as a funnel. At the widest point, about 9 out of 10 people infected with the virus experience either no symptoms or something resembling a mild flu. They recover without ever knowing they had yellow fever. The remaining 10% develop noticeable illness: sudden fever, chills, severe headache, back pain, nausea, and fatigue, typically showing up 3 to 6 days after a mosquito bite. Most of these people improve within a week.
The critical transition happens in roughly 1 out of 7 symptomatic patients (about 12% to 15% of those who get sick). After what feels like recovery, sometimes just a few hours of feeling better, the disease roars back in a far more dangerous form. This brief calm before the storm is one of yellow fever’s most deceptive features.
What Makes Severe Yellow Fever So Lethal
When the disease enters its severe phase, the body’s own immune response becomes part of the problem. Inflammatory signaling spirals out of control, damaging the liver, kidneys, and blood vessels simultaneously. The liver damage causes jaundice, the yellowing of skin and eyes that gives the disease its name. Blood clotting mechanisms break down, leading to internal and external bleeding. Patients can bleed from the mouth, nose, eyes, or stomach. Shock and complete organ failure follow.
There is no antiviral drug that targets yellow fever. Treatment in a hospital is purely supportive: fluids, blood products, and organ support. Even with that care, a recent analysis of hospitalized yellow fever patients in Brazil found an in-hospital mortality rate of 24%. Without hospital access, which is the reality in many rural areas where outbreaks occur, outcomes are worse. The case fatality rate for confirmed severe cases ranges from 30% to 60%, depending on the outbreak and the level of medical infrastructure available.
Recent Outbreaks Show the Virus Still Hits Hard
Yellow fever is not a historical curiosity. In the first four months of 2025 alone, five countries in the Americas reported 212 confirmed cases and 85 deaths, a case fatality rate of 40%. That represents a threefold increase over the 61 confirmed cases reported in all of 2024. Brazil and Colombia accounted for the bulk of cases, each with a 40% fatality rate among confirmed infections. Ecuador reported four cases, all fatal.
These numbers come with a major caveat. Confirmed cases skew toward the sickest patients, because mild infections rarely get tested. The WHO estimates that actual case counts during outbreaks may be 10 to 250 times higher than what gets reported. That means the 40% fatality rate reflects the deadliness of severe, diagnosed disease, not the risk to every person bitten by an infected mosquito. Still, during a large Brazilian epidemic from late 2016 to mid-2018, over 2,050 confirmed cases produced 681 deaths, a fatality rate of 33%. Researchers noted that this high number likely reflected underreporting of milder cases rather than an unusually virulent strain.
Who Faces the Highest Risk
Age and overall health play a significant role in outcomes. Older adults, particularly those with existing chronic conditions, are more susceptible to severe infection. Once infected, they face a higher risk of complications cascading into organ failure and death. This pattern is common across many infectious diseases, but it is especially relevant for yellow fever because the window between manageable illness and life-threatening crisis is so narrow.
Geography matters too, though not because the virus itself differs between continents. Epidemics are more frequent and larger in Africa than in the Americas, largely because of differences in mosquito populations, vaccination coverage, and population density in endemic zones. Clinically, the disease looks the same whether it strikes in Nigeria or Brazil. The variation in reported fatality rates between regions mostly reflects how many mild cases get counted, not a real difference in how dangerous the virus is.
Vaccination Is the Only Reliable Protection
A single dose of the yellow fever vaccine provides strong, long-lasting immunity. The vaccine has been in use since the 1930s and is required for entry into many countries in Africa and South America. Protection develops within about 10 days for most people, and a 2015 international review concluded that a single dose provides lifetime protection for the vast majority of travelers, eliminating the previous requirement for boosters every 10 years.
The vaccine uses a live but weakened version of the virus, which means it carries a very small risk of serious side effects that mimic the disease itself. This rare reaction, called vaccine-associated viscerotropic disease, involves the same kind of multi-organ failure seen in wild yellow fever and can be fatal. The risk is highest in people over 60 and those with weakened immune systems, which is why the decision to vaccinate older travelers involves weighing the tiny vaccine risk against the very real risk of the disease in endemic areas.
For anyone traveling to or living in a region where yellow fever circulates, vaccination remains the single most effective way to take the disease’s lethality off the table entirely. Without it, yellow fever is one of the most dangerous infections a person can encounter in the tropics.